Head-to-head evidence
Topiramate (Qudexy XR) vs Topiramate (Topamax)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: Voltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrase · full Epilepsy pipeline
Topiramate (Qudexy XR)
Marketed by Upsher-Smith Laboratories, LLC
NCT00236717 · Phase 3 · completed
Patients were randomly assigned and the study was double-blinded, comparing topiramate against standard epilepsy medicines in a large group of newly diagnosed patients, using time to first seizure -- a direct clinical outcome -- as the primary measure. However, no results have been reported for this trial, so its actual effect on seizure control cannot be assessed from this record.
Topiramate (Topamax)
Marketed by Johnson & Johnson
NCT00266591 · Phase 3 · completed
The study was randomized and double-blind with 51 participants, and its primary endpoint was the clinical measure of time to withdrawal for therapeutic failure. However, the comparator arm is not identifiable in the available record and no primary-outcome results were posted, so the trial provides limited interpretable evidence.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Topiramate (Qudexy XR)'s landscape · Topiramate (Topamax)'s landscape